Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus OTOBIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus OTOBIONE.
MAGNACORT vs OTOBIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
OTOBIONE is a combination product containing ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
1-2 drops in affected ear(s) twice daily; otic administration only.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
2.5 hours (prolonged to 12-24 hours in renal impairment, CrCl <30 mL/min)
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Renal: 90% unchanged; biliary: <5% as metabolites; fecal: <2%
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid